Literature DB >> 32015025

Comparison of MIC Test Strip and Sensititre YeastOne with the CLSI and EUCAST Broth Microdilution Reference Methods for In Vitro Antifungal Susceptibility Testing of Cryptococcus neoformans.

Fatima Zohra Delma1, Abdullah M S Al-Hatmi2,3,4, Jochem B Buil1,3, Hein van der Lee1,3, Marlou Tehupeiory-Kooreman1,3, G Sybren de Hoog2,3, Joseph Meletiadis5,6, Paul E Verweij7,3.   

Abstract

We compared MIC test strip (MTS) and Sensititre YeastOne (SYO) methods with EUCAST and CLSI methods for amphotericin B, 5-fluocytosine, fluconazole, voriconazole, and isavuconazole against 106 Cryptococcus neoformans isolates. The overall essential agreement between the EUCAST and CLSI methods was >72% and >94% at ±1 and ±2 dilutions, respectively. The essential agreements between SYO and EUCAST/CLSI for amphotericin B, 5-flucytosine, fluconazole, and voriconazole were >89/>93% and between MTS and EUCAST/CLSI were >57/>75%. Very major error rates were low for amphotericin B and fluconazole (<3%) and a bit higher for the other drugs (<8%).
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  CLSI; Cryptococcus neoformans; EUCAST; Liofilchem MIC test strip; Sensititre YeastOne; antifungal susceptibility

Year:  2020        PMID： 32015025      PMCID： PMC7179306          DOI： 10.1128/AAC.02261-19

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  23 in total

1.  Comparative analysis of Etest and broth microdilution method (AFST-EUCAST) for trends in antifungal drug susceptibility testing of Brazilian Cryptococcus neoformans isolates.

Authors:  Amanda L T Dias; Flavia E Matsumoto; Marcia S C Melhem; Eriques G da Silva; Marcos E Auler; Antonio M de Siqueira; Claudete R Paula
Journal:  J Med Microbiol       Date:  2006-12       Impact factor: 2.472

2.  EUCAST Technical Note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds.

Authors: 
Journal:  Clin Microbiol Infect       Date:  2008-10       Impact factor: 8.067

3.  In Vitro Antifungal Susceptibility Testing of Candida Isolates with the EUCAST Methodology, a New Method for ECOFF Determination.

Authors:  J Meletiadis; I Curfs-Breuker; J F Meis; J W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

4.  Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis.

Authors:  E Dannaoui; M Abdul; M Arpin; A Michel-Nguyen; M A Piens; A Favel; O Lortholary; F Dromer
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

5.  Relationship between in vitro activities of amphotericin B and flucytosine and pH for clinical yeast and mold isolates.

Authors:  D T A te Dorsthorst; P E Verweij; J F G M Meis; J W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

6.  Isavuconazole Is Effective for the Treatment of Experimental Cryptococcal Meningitis.

Authors:  Nathan P Wiederhold; Laura Kovanda; Laura K Najvar; Rosie Bocanegra; Marcos Olivo; William R Kirkpatrick; Thomas F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

7.  Comparison of Etests and Vitek 2 ® to broth microdilution for the susceptibility testing of Cryptococcus neoformans.

Authors:  Yesholata Mahabeer; Christina C Chang; Dianithi Naidu; Afton Dorasamy; Sharon Lewin; Thumbi Ndung'u; Mohammed-Yunus Moosa; Martyn French; Koleka Mlisana; Yacoob Coovadia
Journal:  Diagn Microbiol Infect Dis       Date:  2014-09-16       Impact factor: 2.803

8.  Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america.

Authors:  John R Perfect; William E Dismukes; Francoise Dromer; David L Goldman; John R Graybill; Richard J Hamill; Thomas S Harrison; Robert A Larsen; Olivier Lortholary; Minh-Hong Nguyen; Peter G Pappas; William G Powderly; Nina Singh; Jack D Sobel; Tania C Sorrell
Journal:  Clin Infect Dis       Date:  2010-02-01       Impact factor: 9.079

9.  Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole.

Authors:  A Espinel-Ingroff; A I Aller; E Canton; L R Castañón-Olivares; A Chowdhary; S Cordoba; M Cuenca-Estrella; A Fothergill; J Fuller; N Govender; F Hagen; M T Illnait-Zaragozi; E Johnson; S Kidd; C Lass-Flörl; S R Lockhart; M A Martins; J F Meis; M S C Melhem; L Ostrosky-Zeichner; T Pelaez; M A Pfaller; W A Schell; G St-Germain; L Trilles; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2012-09-04       Impact factor: 5.191

Review 10.  The war on cryptococcosis: A Review of the antifungal arsenal.

Authors:  Ahmad Mourad; John R Perfect
Journal:  Mem Inst Oswaldo Cruz       Date:  2018-02-19       Impact factor: 2.743
View more
  3 in total

Review 1.  Drug-Resistant Fungi: An Emerging Challenge Threatening Our Limited Antifungal Armamentarium.

Authors:  Amir Arastehfar; Toni Gabaldón; Rocio Garcia-Rubio; Jeffrey D Jenks; Martin Hoenigl; Helmut J F Salzer; Macit Ilkit; Cornelia Lass-Flörl; David S Perlin
Journal:  Antibiotics (Basel)       Date:  2020-12-08

Review 2.  A Pragmatic Approach to Susceptibility Classification of Yeasts without EUCAST Clinical Breakpoints.

Authors:  Karen Marie Thyssen Astvad; Sevtap Arikan-Akdagli; Maiken Cavling Arendrup
Journal:  J Fungi (Basel)       Date:  2022-01-30

3.  MALDI-TOF MS-Based Clustering and Antifungal Susceptibility Tests of Talaromyces marneffei Isolates from Fujian and Guangxi (China).

Authors:  Lili Fang; Minxue Liu; Chunlan Huang; Jian Guo; Xiaobo Ma; Yanqing Zheng; Wenjuan Wu; Jiangshan Huang; Heping Xu
Journal:  Infect Drug Resist       Date:  2022-07-01       Impact factor: 4.177
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.